Co-Development Agreements

Permits a two-way exchange of materials and information, and assumes exchange of results and/or conclusions will occur between NIH and companies, universities, state/local governments, Federal labs, and non-profits.

• Combines terms of a CDA and MTA
• Simplified research plan
• Exchange of new material created during the collaboration is addressed
• No funding from the outside party allowed
• No license option
• Rights to foreground IP are not addressed
• Human and non-human materials covered

Permits co-development of NIH or outside invention involving companies, universities, state/local governments, Federal labs, and non-profits.

For NIH

• May receive funds or in-kind contributions for collaborative research project
• May provide confidentiality for research results up to five years after development 

For Collaborator

• Exclusive option to license any inventions that are developed by a Federal laboratory employee(s) as part of the collaborative research
• Access to unique reagents and resources
• Access to scientific and regulatory expertise
• Access to Federal lab

CRADA Information Sheet

This information sheet describes the CRADA mechanism. It provides information about:

• CRADA models to capture the various collaboration types
• Characteristics common to all CRADA models
• Collaborator’s rights to the outcome of the CRADA research plan

Transfers material into NIH for research in Human Subjects from companies, state/local governments, non-profits, and universities

• Covers investigational data, drug, diagnostic, or device
• No funding from the outside party required
• No option to license foreground IP
• Clinical and non-clinical
• Addresses regulatory issues and monitoring
• Addresses Personally Identifiable Information (PII)